Blood cancers have seen tremendous advancements in the past few years owing to the dedication of the researchers who are putting their endless efforts just to bring innovation into the lives of suffering patients. These experimentations and their upshots are always brought to us through various platforms, the Ameri...Find More
Antibody-drug conjugate (ADCs) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. Over the past couple of decades, antibody-drug conjugates have revolutionized the field of cancer chemotherapy. ADCs are composed of 3 parts: an antibody drug...Find More
C4X Discovery Holdings and AstraZeneca Signs Exclusive USD 402 Million Global License C4X Discovery Holdings has signed an exclusive global license with AstraZeneca worth up to USD 402 million for the development and commercialization of the NRF2 Activator program. The agreement will allow AstraZeneca to develop...Find More
Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of the total lung cancers in the United States. Almost 230K new cases were diagnosed in 2022 alone. Moreover, significant deaths were recorded at the end of the same year, accounting for almost 130K deaths. As per DelveIn...Find More
Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...Find More
The growth and development in the Digital health technologies, such as mobile health (mHealth) apps, electronic health records (EHRs), electronic medical records (EMRs), wearable devices, telehealth, and telemedicine, as well as personalized medicine, have immensely transformed the healthcare industry and its marke...Find More
Clinical Diagnosis (Dx) is the identification and confirmation of disease or disorder or exposure to xenobiotics to explain the clinical manifestations shown by the patient. It is also performed to assess the state of health of an individual (routine health checkup), functioning of any organ or associated metabolic...Find More
DePuy Synthes Received FDA Approval for TELIGEN™ System On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...Find More
Peripheral T-cell Lymphoma (PTCL) is a diverse disorder category that accounts for 10% to 15% of non-Hodgkin lymphomas. Most PTCL subtypes, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell/T-cell lymphoma, are aggressive (fast-growing) lymphomas. PTCLs are...Find More
It is estimated that around five billion people are on the verge of losing access to essential healthcare services by 2030, for example, mandatory healthcare services, necessary medicine, and visiting healthcare providers. This issue can further become complex if there is an increase in the shortage of trained heal...Find More
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.